Picking apart health care lobbying, from Grindr to Lipton Tea

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Hard bargain or hardly a bargain?

The deadline for Medicare to announce negotiated prices on the first round of drugs is fast approaching. If you’re wondering how to tell whether the Biden administration drove a hard bargain, my colleague John Wilkerson has some tips.

Judging the negotiated prices is not straight forward, but there are at least four ways to get at it. Do they save taxpayers money? Do they save seniors’ money? Are they appropriately priced for the value they provide? Are we still paying more than other countries?

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In